Gautam Baskaran1, Venkataswarup Tiriveedhi2, Sabarinathan Ramachandran2, Aviva Aloush1, Brenda Grossman3, Ramsey Hachem1, Thalachallour Mohanakumar4. 1. Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. 2. Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. 3. Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Surgery, Washington University School of Medicine, St. Louis, Missouri; Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: kumart@wustl.edu.
Abstract
BACKGROUND: Extracorporeal photopheresis (ECP) has been used to treat chronic rejection after lung transplantation (LTx). We investigated the effect of ECP on several immune parameters that have been associated with poor lung function, including donor-specific antibodies (DSA) to human leukocyte antigen (HLA), antibodies against the lung-associated self-antigens (SAg), Kα1-tubulin (Kα1T), collagen I and V, and circulating levels of pro-inflammatory and anti-inflammatory cytokines. METHODS: Sera were collected from post-LTx patients diagnosed with bronchiolitis obliterans before and 6 months after initiation of ECP. DSA and cytokine levels were measured by Luminex (Invitrogen, Carlsbad, CA). Changes in lung function over the 6 months preceding and after the initiation of ECP were measured by retrospective analysis of spirometry performed at routine clinic visits. RESULTS: ECP was associated with a significant decline in DSA levels as well as antibodies to lung-associated SAg. ECP also reduced circulating levels of pro-inflammatory cytokines and increased levels of anti-inflammatory cytokines. These immunologic changes were associated with a significant 63% reduction in the rate of decline in forced expiratory volume in 1 second over a 1-year period. Though statistically insignificant, a higher rate of clearance of antibodies to lung-associated SAg was strongly associated with better response to ECP. CONCLUSIONS: ECP is associated with a reduction in the levels of circulating DSA, antibodies to lung-associated SAg (Kα1T, collagen I, and collagen V), and circulating levels of several pro-inflammatory cytokines. We propose that these changes contribute to the beneficial effect of ECP in reducing the decline in lung function.
BACKGROUND: Extracorporeal photopheresis (ECP) has been used to treat chronic rejection after lung transplantation (LTx). We investigated the effect of ECP on several immune parameters that have been associated with poor lung function, including donor-specific antibodies (DSA) to human leukocyte antigen (HLA), antibodies against the lung-associated self-antigens (SAg), Kα1-tubulin (Kα1T), collagen I and V, and circulating levels of pro-inflammatory and anti-inflammatory cytokines. METHODS: Sera were collected from post-LTxpatients diagnosed with bronchiolitis obliterans before and 6 months after initiation of ECP. DSA and cytokine levels were measured by Luminex (Invitrogen, Carlsbad, CA). Changes in lung function over the 6 months preceding and after the initiation of ECP were measured by retrospective analysis of spirometry performed at routine clinic visits. RESULTS: ECP was associated with a significant decline in DSA levels as well as antibodies to lung-associated SAg. ECP also reduced circulating levels of pro-inflammatory cytokines and increased levels of anti-inflammatory cytokines. These immunologic changes were associated with a significant 63% reduction in the rate of decline in forced expiratory volume in 1 second over a 1-year period. Though statistically insignificant, a higher rate of clearance of antibodies to lung-associated SAg was strongly associated with better response to ECP. CONCLUSIONS: ECP is associated with a reduction in the levels of circulating DSA, antibodies to lung-associated SAg (Kα1T, collagen I, and collagen V), and circulating levels of several pro-inflammatory cytokines. We propose that these changes contribute to the beneficial effect of ECP in reducing the decline in lung function.
Authors: M R Miller; J Hankinson; V Brusasco; F Burgos; R Casaburi; A Coates; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; R Jensen; D C Johnson; N MacIntyre; R McKay; D Navajas; O F Pedersen; R Pellegrino; G Viegi; J Wanger Journal: Eur Respir J Date: 2005-08 Impact factor: 16.671
Authors: L Urbani; A Mazzoni; P Colombatto; G Biancofiore; L Bindi; C Tascini; F Menichetti; M Brunetto; F Scatena; F Filipponi Journal: Transplant Proc Date: 2008-05 Impact factor: 1.066
Authors: Bryan A Whitson; Matthew E Prekker; Cynthia S Herrington; Timothy P M Whelan; David M Radosevich; Marshall I Hertz; Peter S Dahlberg Journal: J Heart Lung Transplant Date: 2007-10 Impact factor: 10.247
Authors: William J Burlingham; Robert B Love; Ewa Jankowska-Gan; Lynn D Haynes; Qingyong Xu; Joseph L Bobadilla; Keith C Meyer; Mary S Hayney; Ruedi K Braun; Daniel S Greenspan; Bagavathi Gopalakrishnan; Junchao Cai; David D Brand; Shigetoshi Yoshida; Oscar W Cummings; David S Wilkes Journal: J Clin Invest Date: 2007-11 Impact factor: 14.808
Authors: James F George; Christie W Gooden; Lingling Guo; Wing Hong Guo; James K Kirklin Journal: J Heart Lung Transplant Date: 2008-06 Impact factor: 10.247
Authors: Scott M Palmer; R Duane Davis; Denis Hadjiliadis; Marshall I Hertz; David N Howell; Fran E Ward; Kay Savik; Nancy L Reinsmoen Journal: Transplantation Date: 2002-09-27 Impact factor: 4.939
Authors: Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Sci Transl Med Date: 2017-07-12 Impact factor: 17.956
Authors: Alberto Benazzo; Nina Worel; Stefan Schwarz; Ulrike Just; Anna Nechay; Christoph Lambers; Georg Böhmig; Gottfried Fischer; Daniela Koren; Gabriela Muraközy; Robert Knobler; Walter Klepetko; Konrad Hoetzenecker; Peter Jaksch Journal: Transfus Med Hemother Date: 2020-05-05 Impact factor: 3.747
Authors: Ashwini Arjuna; Michael T Olson; Rajat Walia; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Expert Rev Respir Med Date: 2020-10-25 Impact factor: 3.772